

**From:** [Nguyen, Janice](mailto:Nguyen_Janice)  
**To:** [regulatoryaffairs@zevacor.com](mailto:regulatoryaffairs@zevacor.com)  
**Cc:** [Parker, Bryan](mailto:Parker_Bryan)  
**Subject:** NRC Request for Additional Information for Change of Control of Zevacor Pharma, Inc. (Mail Control Number 599643)  
**Date:** Friday, June 09, 2017 4:10:00 PM

---

Licensee: Zevacor Pharma, Inc.  
License Number: 45-25221-01MD  
Docket Number: 030-32974  
Mail Control Number: 599643

Dear Mr. Plastini,

**Could you please reply back to this email to confirm receipt?**

This is in response to your amendment request dated May 15, 2017, which appears to be an indirect change of ownership of Zevacor Pharma, Inc. to Sofie Network, Inc. In order to continue our review, please provide the following additional information:

1. Please describe any planned change in members on the Board of Directors, etc.
2. Please describe any changes in the radiation safety program, use, possession, or waste management that relate to the licensed program.
3. Describe the status of the licensee's facilities, equipment, and radiation safety program, including any known contamination and whether decontamination will occur prior to transfer. Include the status of calibrations, leak tests, area surveys, wipe tests, training, quality control, and related records. Since decommissioning is not anticipated at this current time, please describe any contamination and confirm that the transferee is knowledgeable of the extent and levels of contamination and applicable decommissioning requirements.
4. It is our understanding that operations will continue through the transfer process. If this understanding is correct, provide either an agreement to perform a survey confirming that the facility is free of contamination or an agreement by the transferee to accept the facility "as is" on the date of transfer.
5. Please confirm that both transferor and transferee agree to transferring control of the licensed material and activity, and the conditions of transfer, and that the transferee has been made aware of any open inspection items and their responsibility for possible resulting enforcement actions.
6. Please confirm that both transferor and transferee will abide by all constraints, conditions, requirements, representations, and commitments of the transferor or that the transferee will submit a complete description of the proposed licensed program.
7. Timothy D. Stone, Jr. is currently listed as the President and Chief Executive Officer (CEO) of Zevacor Pharma, Inc. Please confirm that Mr. Stone is also the President and CEO of Illinois Health and Science. After the change of control, please indicate if Mr. Stone will remain President and CEO of Zevacor Pharma, Inc. If not, please

indicate his replacement.

8. In order for the NRC to determine if this indirect change of control is to a “known entity,” please indicate if Sofie Network, Inc. possesses any NRC or Agreement State licenses. If so, please provide a copy.

Please note that Region III will be doing their review of Zevacor Pharma, Inc.’s change of control (NRC License Number 45-25221-05) concurrently with Region I. Upon review of the change by Region III, there may be additional questions.

The above information is taken from NUREG-1556, Volume 15, Revision 1, “Consolidated Guidance About Materials Licenses: Program-Specific Guidance About Changes of Control and About Bankruptcy Involving Byproduct, Source, or Special Nuclear Material Licenses.” The notice of the proposed sale was posted to the NRC’s website on June 8, 2017 and, per 10 CFR 2.1305, the public has 30 days to provide comments for the NRC’s consideration. Therefore, the NRC would provide approval no earlier than 30 days after June 8, 2017. If Zevacor Pharma, Inc. or Sofie Network, Inc.’s representatives have questions, please feel free to contact me. The NRC is only concerned that control of the license and licensed activities and materials are not transferred prior to NRC’s written approval. Any aspect of the sale that does not affect control of the license can, of course, proceed without NRC’s approval.

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov)<<http://www.nrc.gov>>; select Nuclear Materials; Med, Ind, & Academic Uses; then Licensee Toolkits, see our toolkit index page. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

You may respond to my attention in writing by letter, email (if letter is signed by senior management and scanned into a pdf format), or fax (610-337-5269), referencing mail control number 599643. If we do not receive a reply from you within 30 days, we will assume that you do not wish to pursue your application.

The NRC’s Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency’s *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC’s safety culture Web site at <http://www.nrc.gov/about-nrc/safety-culture.html>. We strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities.”

Thank you for your cooperation. Please feel free to contact me by telephone or e-mail if you have any questions.

*Jan Nguyen*

Janice Nguyen  
Senior Health Physicist  
Division of Nuclear Materials Safety

U.S. Nuclear Regulatory Commission Region I  
2100 Renaissance Boulevard, Suite 100  
King of Prussia, PA 19406-2713  
(610) 337-5006  
FAX (610) 337-5269